MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome that has become a reference tool for studying how mitochondria signal to the rest of the cell. This review summarises, for research audiences, what the published literature actually reports about MOTS-c and glucose homeostasis across cell, rodent, and human observational studies.

What MOTS-c is, and where it comes from

For most of the twentieth century, mitochondria were framed almost exclusively as the cell’s power plants. That picture has widened. Mitochondria carry their own small circular genome, and within it are short open reading frames (sORFs) that encode a family of bioactive peptides now called mitochondrial-derived peptides. MOTS-c — mitochondrial open reading frame of the 12S rRNA type-c — is one of them, a 16-amino-acid peptide identified within the mitochondrial 12S ribosomal RNA region.¹ Its discovery followed that of humanin and extended the idea that the mitochondrial genome does not only build the respiratory chain; it also issues signalling molecules that act well beyond the organelle.¹

Several features make MOTS-c a useful object of study. It is detectable in plasma as well as in tissues, and reported circulating concentrations decline with age.³ Under metabolic stress the peptide has been observed to move from the cytoplasm into the nucleus, where it associates with stress-response gene programmes.⁴ This combination — a diffusible peptide, an age-linked expression profile, and a stress-responsive nuclear role — is why researchers frame MOTS-c as part of a mitochondrial-to-nuclear “retrograde” signalling network rather than as a simple metabolite.⁴

The proposed mechanism: folate cycle to AMPK

The mechanism most consistently reported in the primary literature runs through cellular energy sensing. In the original characterisation, MOTS-c was shown to inhibit the folate one-carbon cycle and its tethered de novo purine biosynthesis. That inhibition causes the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) to accumulate, and AICAR is a known activator of AMP-activated protein kinase (AMPK).¹ AMPK is the cell’s master low-energy sensor: when activated it shifts metabolism toward catabolic, energy-generating pathways, including glucose uptake and fatty-acid oxidation.

Review syntheses have consolidated this into what is often written as the folate–AICAR–AMPK axis, and have added the observation that under stress MOTS-c translocates to the nucleus and interacts with genes bearing antioxidant response elements (ARE).⁴ Downstream, work compiled in mechanistic reviews links MOTS-c activity to regulation of specific effectors relevant to glucose handling, including the glucose transporter GLUT4 and signalling nodes such as STAT3 and the anti-inflammatory cytokine IL-10.⁵ A parallel line of human ex vivo work reports that MOTS-c can engage AKT- and AMPK-dependent pathways associated with insulin sensitivity.¹⁰

Two caveats belong here. First, most of this mechanistic detail derives from cell lines and rodent tissue, not from intact human physiology. Second, the folate-cycle model is the dominant but not the only proposed route; reviews note additional regulatory interactions that remain under active investigation.⁵ The mechanism is best described as plausible and partially mapped rather than fully settled.

Skeletal muscle and glucose uptake

Across the literature, skeletal muscle recurs as the tissue where MOTS-c is most often studied in the context of glucose. The original report identified skeletal muscle as the apparent primary target organ, with MOTS-c treatment influencing insulin sensitivity there.¹ Because skeletal muscle accounts for a large share of insulin-stimulated glucose disposal, a peptide that modulates AMPK signalling in that tissue is mechanistically interesting for anyone modelling glucose homeostasis.

Later studies reinforced the muscle focus. A review dedicated to MOTS-c summarised evidence that the peptide improves glucose metabolism in skeletal muscle and framed this as the throughline connecting its reported effects in obesity, aging, and diabetes models.³ In experimental gestational-diabetes work, MOTS-c administration was reported to activate insulin sensitivity in the skeletal muscle of affected mice and to raise glucose uptake in cultured muscle cells in vitro.⁶ The consistent picture in these models is that MOTS-c pushes muscle cells toward increased glucose uptake, plausibly via AMPK and GLUT4, though the precise stoichiometry between pathway steps is still being characterised.

Evidence from rodent metabolic models

The strongest interventional evidence — meaning studies where MOTS-c was actually administered and outcomes measured — comes from rodents. In the founding study, MOTS-c treatment in mice was reported to prevent both age-dependent and high-fat-diet-induced insulin resistance, and to blunt diet-induced obesity.¹ These results established MOTS-c as a candidate regulator of organismal, not just cellular, metabolic balance.

Subsequent rodent work extended the range of models:

• Gestational diabetes model. In mice made hyperglycaemic by a high-fat diet plus low-dose streptozotocin, daily MOTS-c during pregnancy was reported to lower blood glucose, improve glucose and insulin tolerance, and reduce adverse reproductive outcomes; the authors also reported a protective effect on pancreatic beta-cells in that model.⁶
• Accelerated-aging model. In D-galactose-treated mice, exogenous MOTS-c was associated with reduced aberrant lipid deposition in liver, visceral fat, and skin, alongside changes in mitochondrial-dynamics markers — with only mild effects on blood glucose in that particular paradigm.⁷
• Physical-capacity model. In young, middle-aged, and old mice, MOTS-c enhanced physical performance and regulated nuclear genes tied to metabolism and proteostasis in skeletal muscle, connecting the peptide’s metabolic and functional readouts.²

These are convergent, independent rodent findings, which strengthens the preclinical case. They do not, on their own, establish anything about human glucose control — a limitation the primary authors themselves are careful to state.

What human observational cohorts report

Human MOTS-c research is dominated by a different study design: measuring endogenous circulating MOTS-c and correlating it with metabolic phenotype. This is associative work, and it cannot establish cause and effect, but the pattern across independent cohorts is notably consistent — lower circulating MOTS-c tends to track with more adverse metabolic status.

Two nuances deserve emphasis. First, the direction of association is not uniform: while diabetes and sleep-apnoea cohorts report lower MOTS-c with worse metabolic status,⁸¹¹ a study in non-diabetic participants reported the opposite — higher plasma MOTS-c alongside greater liver and android fat — which the authors interpreted as a compensatory, hormetic stress response rather than a marker of health.¹² Second, sex differences recur: several cohorts detected the clearest associations in males.⁹ Circulating MOTS-c is therefore best treated as a context-dependent correlate, not a clean biomarker with a single interpretation.

A genetic clue: the K14Q polymorphism

One of the more compelling lines of human evidence is genetic rather than interventional. An Asian-specific mitochondrial DNA variant (m.1382A>C) produces a single amino-acid substitution in MOTS-c, replacing lysine-14 with glutamine (K14Q). In a meta-analysis of three cohorts totalling more than 27,000 people, male carriers of the C-allele showed a higher prevalence of type 2 diabetes, and the effect was most pronounced among physically inactive men — what the authors termed a “kinesio-genomic” interaction.¹³

The same study paired the population data with function: high-fat-fed male mice injected with normal MOTS-c showed reduced weight and improved glucose tolerance, whereas mice given the K14Q variant did not, and the variant peptide showed diminished insulin-sensitising activity in cells.¹³ This bench-to-population coherence — a naturally occurring variant that both weakens MOTS-c function and tracks with diabetes risk — is stronger evidence for a genuine role in glucose homeostasis than any single correlational study, even though it still does not test administered peptide in humans.

Exercise as an endogenous inducer

MOTS-c is not only something researchers administer; it is also produced by the body, and physical activity appears to be a physiological trigger. In work spanning mice and humans, exercise was reported to induce endogenous MOTS-c expression in skeletal muscle and in circulation, and late-life intermittent MOTS-c treatment increased physical capacity in mice.² This positions MOTS-c within the broader biology of exercise adaptation and helps explain why baseline levels and exercise history complicate the interpretation of any single measurement.

The exercise link also connects back to the genetics. Because the K14Q effect on diabetes prevalence was concentrated in sedentary men, the data hint that endogenous MOTS-c signalling and physical activity may operate along overlapping pathways — an interaction that has become a recurring theme in the field’s framing of the peptide.¹³ For researchers, this means that studies of MOTS-c and glucose cannot cleanly separate the peptide from the activity state of the model. Interest in mitochondrial signalling more broadly has also driven parallel study of cofactor-based tools such as NAD+ in metabolic research, though those act through distinct mechanisms.

How strong is the evidence, really?

It is worth stating the evidence hierarchy plainly, because the gap between rodent and human data is the single most important thing to understand about MOTS-c and glucose homeostasis. The mechanistic and interventional backbone — folate-cycle inhibition, AMPK activation, improved glucose handling after administration — is built on cell-culture and rodent studies.¹⁶ The human literature is overwhelmingly observational and cross-sectional, showing that endogenous MOTS-c concentrations correlate with metabolic phenotypes but not that administering the peptide changes those phenotypes in people.⁸¹²

The genetic evidence adds weight by linking a loss-of-function variant to diabetes risk in a large population, which is harder to explain by confounding than a simple correlation.¹³ But the field still lacks the study design that would settle the question: a controlled trial of administered MOTS-c with glycaemic endpoints in humans. Reviews consistently note that clinical translation remains undeveloped and that no established clinical application exists.³ For laboratory teams, MOTS-c is therefore a well-motivated mechanistic probe and a candidate signalling molecule — not a validated intervention. Consistent, well-characterised MOTS-C material and careful attention to model choice and activity state are the practical prerequisites for interpretable results.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.